RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/19846776http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/19846776http://www.w3.org/2000/01/rdf-schema#comment"Patients with neurofibromatosis type 1 (NF1) carry approximately a 10% lifetime risk of developing a malignant peripheral nerve sheath tumor (MPNST). Although the molecular mechanisms underlying NF1 to MPNST malignant transformation remain unclear, alterations of both the RAS/RAF/MAPK and PI3K/AKT/mTOR signaling pathways have been implicated. In a series of genetically engineered murine models, we perturbed RAS/RAF/MAPK or/and PTEN/PI3K/AKT pathway, individually or simultaneously, via conditional activation of K-ras oncogene or deletion of Nf1 or Pten tumor suppressor genes. Only K-Ras activation in combination with a single Pten allele deletion led to 100% penetrable development of NF lesions and subsequent progression to MPNST. Importantly, loss or decrease in PTEN expression was found in all murine MPNSTs and a majority of human NF1-associated MPNST lesions, suggesting that PTEN dosage and its controlled signaling pathways are critical for transformation of NFs to MPNST. Using noninvasive in vivo PET-CT imaging, we demonstrated that FDG can be used to identify the malignant transformation in both murine and human MPNSTs. Our data suggest that combined inhibition of RAS/RAF/MAPK and PTEN/PI3K/AKT pathways may be beneficial for patients with MPNST."xsd:string
http://purl.uniprot.org/citations/19846776http://purl.org/dc/terms/identifier"doi:10.1073/pnas.0910398106"xsd:string
http://purl.uniprot.org/citations/19846776http://purl.uniprot.org/core/author"Liu X."xsd:string
http://purl.uniprot.org/citations/19846776http://purl.uniprot.org/core/author"Wu H."xsd:string
http://purl.uniprot.org/citations/19846776http://purl.uniprot.org/core/author"Dang J."xsd:string
http://purl.uniprot.org/citations/19846776http://purl.uniprot.org/core/author"Mischel P.S."xsd:string
http://purl.uniprot.org/citations/19846776http://purl.uniprot.org/core/author"Nakashima J."xsd:string
http://purl.uniprot.org/citations/19846776http://purl.uniprot.org/core/author"Ao Y."xsd:string
http://purl.uniprot.org/citations/19846776http://purl.uniprot.org/core/author"Parada L.F."xsd:string
http://purl.uniprot.org/citations/19846776http://purl.uniprot.org/core/author"Sofroniew M.V."xsd:string
http://purl.uniprot.org/citations/19846776http://purl.uniprot.org/core/author"Smith K.B."xsd:string
http://purl.uniprot.org/citations/19846776http://purl.uniprot.org/core/author"Gregorian C."xsd:string
http://purl.uniprot.org/citations/19846776http://purl.uniprot.org/core/author"Mellinghoff I.K."xsd:string
http://purl.uniprot.org/citations/19846776http://purl.uniprot.org/core/author"Phelps M."xsd:string
http://purl.uniprot.org/citations/19846776http://purl.uniprot.org/core/author"Lawson G."xsd:string
http://purl.uniprot.org/citations/19846776http://purl.uniprot.org/core/author"Nghiemphu P.L."xsd:string
http://purl.uniprot.org/citations/19846776http://purl.uniprot.org/core/author"Dry S.M."xsd:string
http://purl.uniprot.org/citations/19846776http://purl.uniprot.org/core/author"Eilber F.C."xsd:string
http://purl.uniprot.org/citations/19846776http://purl.uniprot.org/core/date"2009"xsd:gYear
http://purl.uniprot.org/citations/19846776http://purl.uniprot.org/core/name"Proc Natl Acad Sci U S A"xsd:string
http://purl.uniprot.org/citations/19846776http://purl.uniprot.org/core/pages"19479-19484"xsd:string
http://purl.uniprot.org/citations/19846776http://purl.uniprot.org/core/title"PTEN dosage is essential for neurofibroma development and malignant transformation."xsd:string
http://purl.uniprot.org/citations/19846776http://purl.uniprot.org/core/volume"106"xsd:string
http://purl.uniprot.org/citations/19846776http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/19846776